Stockscreener 앱 받기
1.06
26.99%
0.2253
전일 마감가:
$0.8347
열려 있는:
$0.889
하루 거래량:
4.65M
Relative Volume:
4.25
시가총액:
$114.06M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-4.0076
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
+19.65%
1개월 성능:
+6.00%
6개월 성능:
+3.92%
1년 성능:
+37.29%
1일 변동 폭
$0.8347
$1.10
1주일 범위
$0.789
$1.10
52주 변동 폭
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.06 | 89.82M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Oncolytics Biotech (NASDAQ:ONCY) Insider Purchases $25,456.00 in Stock - MarketBeat
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) CEO Acquires 29,500 Shares of Stock - MarketBeat
Patricia Andrews Acquires 35,400 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) CFO Kirk Look Acquires 12,000 Shares - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Director Wayne Pisano Buys 30,000 Shares - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Insider Thomas Charles Heineman Purchases 12,132 Shares - MarketBeat
Will Oncolytics Biotech Inc. outperform tech stocksChart Signals & Weekly High Return Opportunities - mfd.ru
Why retail investors favor Oncolytics Biotech Inc. stockWeekly Trade Review & Detailed Earnings Play Strategies - mfd.ru
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% HigherHere's Why - MarketBeat
Is Oncolytics Biotech Inc. forming a breakout patternMarket Trend Summary & Reliable Breakout Forecasts - mfd.ru
Precision Biologics Market Awakens to $71 Billion Opportunity - Intellectia AI
New Highs: How sensitive is Oncolytics Biotech Inc to inflation2025 Bull vs Bear & Safe Capital Growth Stock Tips - baoquankhu1.vn
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - MSN
Oncolytics Biotech Receives FDA Fast Track Designation - Intellectia AI
$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Oncolytics receives FDA Fast Track Designation for pelareorep - Yahoo Finance
ONCY stock rallies on second fast track designation for experimental cancer drug - MSN
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Oncolytics Biotech receives FDA Fast Track for pelareorep - TipRanks
Oncolytics Biotech Inc Receives FDA Fast Track Designation for Pelareorep - TradingView
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Oncolytics Biotech receives FDA fast track designation for pelareorep in 2L KRAS-mutant MSS metastatic colorectal cancer - marketscreener.com
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Trea - GuruFocus
Oncolytics surges on Fast Track status for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics Biotech stock soars after FDA grants Fast Track Designation By Investing.com - Investing.com South Africa
Oncolytics Biotech stock soars after FDA grants Fast Track Designation - Investing.com
Oncolytics (ONCY) Secures FDA Fast Track for Innovative Cancer T - GuruFocus
Oncolytics Biotech Showcases Promising Immunotherapy Advancements - timothysykes.com
FDA grants fast track designation to Oncolytics’ pelareorep for colorectal cancer - Investing.com
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer - The Manila Times
Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line KRAS-Mutant MSS Metastatic Colorectal Cancer Following Promising Clinical Data - Quiver Quantitative
Oncolytics Biotech® Receives FDA Fast Track Designation for - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Investment Review: Does Entergy Texas Inc have a sustainable dividendJuly 2025 Snapshot & Safe Swing Trade Setup Alerts - baoquankhu1.vn
EPS Watch: Can Oncolytics Biotech Inc expand its profit marginsQuarterly Trade Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Stock Report: Is Oncolytics Biotech Inc forming a breakout pattern - baoquankhu1.vn
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - The Globe and Mail
Record $2.5B Sector Start Spotlights Clinical Oncology Plays - Baystreet.ca
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium - PR Newswire
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - The Globe and Mail
Late-Stage Breakthroughs: How 2026’s Top Clinical Platforms Are Redefining Cancer Treatment - Cantech Letter
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - Cantech Letter
Performance Recap: What is Oncolytics Biotech Incs 5 year growth outlookJuly 2025 Macro Moves & Community Consensus Trade Alerts - baoquankhu1.vn
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge - Intellectia AI
Oncolytics Biotech Strengthens Leadership for Oncology Trials - Intellectia AI
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oncolytics Biotech Inc 주식 (ONCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
| Aromando Andrew | Chief Business Officer |
Feb 11 '26 |
Buy |
0.86 |
29,600 |
25,418 |
55,100 |
| Andrews Patricia S | Director |
Feb 12 '26 |
Buy |
0.86 |
35,400 |
30,292 |
78,128 |
1.12%
0.87%
자본화:
|
볼륨(24시간):